Synthetic analog · 44 amino acids · 4,858 Da

Lixisenatide studies and research data

PepBank has 116 lixisenatide studies with results. 115 of them gave lixisenatide, with 768 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 768 results and 426 papers. Newer studies from Europe PMC

Results in people

652

85% of 768 results

Results in animals

11% of 768 results

Results in lab cells

4% of 768 results

From computer models

0% of 768 results

The molecule

Lixisenatide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Lixisenatide is a 44-residue peptide agonist of the GLP-1 receptor. The US label concerns glucose control in adults with type 2 diabetes. Single-ingredient and insulin combination products differ.

Kind: Synthetic analog · 44 residues
Identifiers: ChEMBLCHEMBL2108336 (opens in a new tab)PubChem CID90472060 (opens in a new tab)UNII74O62BB01U (opens in a new tab)DrugBankDB09265 (opens in a new tab)CAS320367-13-3
Parent: Analog of ExenatideLixisenatide is an exendin-4 analogue. Exenatide is synthetic exendin-4. The GSRS systematic name specifies deletion of Pro38 and addition of six C-terminal L-lysine residues, with terminal amidation.
Development: Approved in the US (Adlyxin, 2016)FDA approval establishes the highest development stage. US marketing availability was not independently established. EU Lyxumia withdrawal concerns the single-ingredient product. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Glucagon-like peptide 1 receptorGLP1RP43220 (opens in a new tab)	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

44 amino acids

H-

HGEGTFTSDL

SKQMEEEAVR

LFIEWLKNGG

PSSGAPPSKK

KKKK

Alignment to Exenatide

Calculated from the two sequences. Curated notes are shown as given.

37 of 39 aligned residues identical (95%) · 2 substitutions · 5 added residues · Exenatide 1–39

Top row: Exenatide (parent)
Bottom row: Lixisenatide

HGEGTFTSDL

SKQMEEEAVR

LFIEWLKNGG

PSSGAPP

Same as parent
Substituted
Non-canonical or D-form
Added
Gap
Modified side chain or end

Differences from the parent

1Parent 38 · analog 38Pro → Ser · Substitution
2Parent 39 · analog 39Ser → Lys · Substitution
3Not in parent · analog 40+ Lys · Added residue
4Not in parent · analog 41+ Lys · Added residue
5Not in parent · analog 42+ Lys · Added residue
6Not in parent · analog 43+ Lys · Added residue
7Not in parent · analog 44+ Lys · Added residue

Basis: Lixisenatide is an exendin-4 analogue. Exenatide is synthetic exendin-4. The GSRS systematic name specifies deletion of Pro38 and addition of six C-terminal L-lysine residues, with terminal amidation.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S
Molecular weight: 4,858 g/mol
Monoisotopic mass: 4,855.5443 Da

GSRS UNII 74O62BB01U(opens in a new tab)retrieved 2026-10-27
PubChem CID 90472060(opens in a new tab)retrieved 2026-10-27
Curated Adlyxin US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 4,858.55 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 4,855.5442 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy FindMod
Isoelectric point (pI): 10.58; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 4.05; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −1.109; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 5,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 53.56; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 46.6; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 2.24 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.708; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 10.58Bjellqvist (ExPASy) 9.78IPC peptide 10.33IPC protein 8.96

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 10.58 · Net charge at pH 7.4: 4.05

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.

Show as table

pH	Net charge
0	11.00
1	10.99
2	10.95
3	10.52
4	8.23
5	5.60
6	4.83
7	4.22
8	3.82
9	3.16
10	1.94
11	−1.93
12	−4.77
13	−5.71
14	−5.96

Composition

Hydrophobic18% (8)A I L M V
Aromatic7% (3)F W
Positive23% (10)H K R
Negative14% (6)D E
Polar20% (9)N Q S T
Special18% (8)G P

44 residues. Each residue counts in one class; F and W count as aromatic.

A Ala2 · 5%

I Ile1 · 2%

L Leu3 · 7%

M Met1 · 2%

V Val1 · 2%

F Phe2 · 5%

W Trp1 · 2%

Y Tyr0 · 0%

H His1 · 2%

K Lys8 · 18%

R Arg1 · 2%

D Asp1 · 2%

E Glu5 · 11%

N Asn1 · 2%

Q Gln1 · 2%

S Ser5 · 11%

T Thr2 · 5%

C Cys0 · 0%

G Gly5 · 11%

P Pro3 · 7%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Lixisenatide has 44 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 90472060(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.141
μH, best 11-residue window: 0.708
Arrow direction: 274°
Residues: 44 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	H	0°	-0.40
2	G	100°	0.48
3	E	200°	-0.74
4	G	300°	0.48
5	T	40°	-0.05
6	F	140°	1.19
7	T	240°	-0.05
8	S	340°	-0.18
9	D	80°	-0.90
10	L	180°	1.06
11	S	280°	-0.18
12	K	20°	-1.50
13	Q	120°	-0.85
14	M	220°	0.64
15	E	320°	-0.74
16	E	60°	-0.74
17	E	160°	-0.74
18	A	260°	0.62
19	V	0°	1.08
20	R	100°	-2.53
21	L	200°	1.06
22	F	300°	1.19
23	I	40°	1.38
24	E	140°	-0.74
25	W	240°	0.81
26	L	340°	1.06
27	K	80°	-1.50
28	N	180°	-0.78
29	G	280°	0.48
30	G	20°	0.48
31	P	120°	0.12
32	S	220°	-0.18
33	S	320°	-0.18
34	G	60°	0.48
35	A	160°	0.62
36	P	260°	0.12
37	P	0°	0.12
38	S	100°	-0.18
39	K	200°	-1.50
40	K	300°	-1.50
41	K	40°	-1.50
42	K	140°	-1.50
43	K	240°	-1.50
44	K	340°	-1.50

Results by area

Lixisenatide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Lixisenatide has 428 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

116 of 426 studies have results (27%), published 2010 to 2026. Top row: every study. Bottom row: studies with results about Lixisenatide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies426 in all, 2010 to 2026

Studies with results116 in all, 2010 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Lixisenatide studies on blood sugar

353 results · people 345 · animals 7 · lab 1

Top 5 of 353 results

In adults with diabetes on metformin, lixisenatide met the trial's noninferiority criterion despite a numerically smaller HbA1c reduction than exenatide.Diabetes care, 2013
In type 1 diabetes, lixisenatide reduced glucagon exposure after a mixed meal compared with placebo.Endocrinology, diabetes & metabolism, 2020
In Japanese patients with type 2 diabetes, adding lixisenatide to glargine reduced HbA1c more than glargine.Diabetes, obesity & metabolism, 2020
In insulin-treated people with diabetes, HbA1c was lower after lixisenatide than placebo.Diabetes care, 2016
In Japanese adults with type 2 diabetes, adding lixisenatide to glargine reduced HbA1c more than glargine alone with metformin.Diabetes, obesity & metabolism, 2020

Lixisenatide studies on side effects

155 results · people 155 · animals 0 · lab 0

Top 5 of 155 results

During Ramadan fasting, symptomatic low blood sugar was numerically lower with lixisenatide (3.3%) than with sulfonylurea (8.9%), each with basal insulin.Diabetes research and clinical practice, 2019
In Japanese patients with diabetes, nausea was less frequent with two-step lixisenatide than one-step lixisenatide through week 24.Journal of diabetes and its complications, 2015
In Japanese patients with diabetes, discontinuation was more frequent with two-step lixisenatide than one-step through week 24, mainly from side effects.Journal of diabetes and its complications, 2015
In patients with diabetes on metformin, pulse increased less with lixisenatide than liraglutide.Diabetes care, 2016
In patients with diabetes and recent coronary events, lixisenatide was not linked to more pancreas inflammation than placebo.The New England journal of medicine, 2015

Lixisenatide studies on weight and appetite

43 results · people 42 · animals 1 · lab 0

Top 5 of 43 results

In patients with diabetes on basal insulin, lixisenatide reduced body weight more than placebo.Diabetes, obesity & metabolism, 2018
In healthy participants after lixisenatide, energy intake was not linked to total stomach content.Nutrients, 2020
In healthy participants, lixisenatide reduced meal energy intake compared with placebo.Nutrients, 2020
Lixisenatide reduced body weight more than placebo in nonfrail older patients with type 2 diabetes.Diabetes care, 2017
In healthy participants after lixisenatide, energy intake was not linked to upper stomach content.Nutrients, 2020

Lixisenatide studies on kidneys and bladder

26 results · people 25 · animals 1 · lab 0

Top 4 of 26 results

In patients with diabetes, lixisenatide did not affect kidney filtration after a meal compared with insulin glulisine.Diabetes, obesity & metabolism, 2017
In people with diabetes and kidney disease in a lixisenatide trial, Klotho levels did not change significantly.Diabetes, obesity & metabolism, 2026
In patients with diabetes, lixisenatide increased absolute and fractional sodium, chloride, and potassium excretion after breakfast versus insulin glulisine.American journal of physiology. Renal physiology, 2019
Doubling of a kidney blood marker was numerically more frequent with lixisenatide than placebo, but the difference was not statistically significant.The lancet. Diabetes & endocrinology, 2018

Lixisenatide studies on stomach and gut

23 results · people 23 · animals 0 · lab 0

Top 5 of 23 results

Lixisenatide slowed gastric emptying versus placebo in healthy participants.Diabetes, obesity & metabolism, 2019
In adults with diabetes, reflux episodes were numerically fewer with lixisenatide than liraglutide, without a significant difference.Diabetes care, 2020
In healthy participants, lixisenatide slowed stomach emptying compared with placebo.Nutrients, 2020
In patients with diabetes on insulin glargine, lixisenatide delayed stomach emptying more than the lower liraglutide dose.Diabetes care, 2015
In totally pancreatectomised individuals, lixisenatide slowed stomach emptying compared with placebo.Diabetologia, 2020

Lixisenatide studies on heart and blood vessels

43 results · people 17 · animals 20 · lab 6

Top 5 of 43 results

After breakfast, upper blood pressure tended to be higher with lixisenatide than with insulin glulisine.Hypertension, 2018
Lixisenatide did not change fasting circulation measurements compared with insulin glulisine in patients with type 2 diabetes.Hypertension, 2018
In people with diabetes and kidney disease, lixisenatide did not significantly change aortic stiffness compared with placebo.Diabetes, obesity & metabolism, 2026
In patients with diabetes and recent coronary events, lixisenatide met noninferiority criteria versus placebo but did not significantly reduce composite cardiovascular events.The New England journal of medicine, 2015
In rabbits, lixisenatide increased fibrotic plaque components compared with saline.Atherosclerosis, 2017

Lixisenatide studies on receptors and cell signals

45 results · people 16 · animals 17 · lab 12

Top 5 of 45 results

Lixisenatide slowed stomach emptying in the study comparing it with insulin glulisine.Hypertension, 2018
In participants with diabetes, lixisenatide reduced fusiform gyrus activation more in obese than lean participants for the specified food cues.Diabetes & metabolism journal, 2020
In patients with diabetes, plasma renin was reported as unchanged with lixisenatide.Diabetes, obesity & metabolism, 2017
In patients receiving lixisenatide, slower stomach emptying statistically explained blood pressure changes after breakfast.Hypertension, 2018
In cells, lixisenatide and exendin-4 showed equal binding affinity.British journal of pharmacology, 2020

Lixisenatide studies on blood levels and clearance

13 results · people 11 · animals 2 · lab 0

Top 5 of 13 results

In healthy subjects, lixisenatide doses ≥5 µg reduced acetaminophen absorption versus placebo.Diabetes/metabolism research and reviews, 2015
In animals, lixisenatide crossed the brain barrier at all tested doses at 30 minutes.BMC neuroscience, 2012
In children and adolescents with diabetes, higher lixisenatide doses generally produced higher drug concentrations regardless of antibody status.Pediatric diabetes, 2022
In animals, lixisenatide crossed the brain barrier at 3 hours.BMC neuroscience, 2012
In the healthy-subject and diabetes studies, lixisenatide reached its highest concentration after 2 h.Diabetes, obesity & metabolism, 2014

Lixisenatide studies on cholesterol and blood fats

9 results · people 9 · animals 0 · lab 0

Top 3 of 9 results

Lixisenatide reduced CM-TAG pool size versus placebo in obese men with diabetes.The Journal of clinical endocrinology and metabolism, 2019
In patients with diabetes, triglycerides increased less with iGlarLixi than insulin glargine at week 30.Diabetes, obesity & metabolism, 2019
Lixisenatide did not reduce VLDL-TAG pool size versus placebo in obese men with diabetes.The Journal of clinical endocrinology and metabolism, 2019

Lixisenatide studies on daily life and fitness

5 results · people 5 · animals 0 · lab 0

5 results

In early Parkinson's disease, motor disability progressed less with lixisenatide than placebo at 12 months.The New England journal of medicine, 2024
Treatment satisfaction was similar with lixisenatide and vildagliptin in Japanese patients receiving background insulin glargine.Diabetes therapy, 2018
In early Parkinson's disease, other secondary results were similar with lixisenatide and placebo.The New England journal of medicine, 2024
In patients with diabetes, satisfaction changes were comparable with lixisenatide before the main meal versus breakfast.Journal of diabetes and its complications, 2014
In early Parkinson's disease, motor scores after washout were lower after lixisenatide than placebo.The New England journal of medicine, 2024

Lixisenatide studies on survival and serious illness

2 results · people 2 · animals 0 · lab 0

2 results

In patients with diabetes and recent coronary events, death rates did not differ significantly between lixisenatide and placebo.The New England journal of medicine, 2015
In children and adolescents with diabetes receiving lixisenatide, no treatment-emergent adverse events resulted in death.Pediatric diabetes, 2022

Lixisenatide studies on use, access and costs

2 results · people 2 · animals 0 · lab 0

2 results

In patients with diabetes, lixisenatide reduced daily basal insulin dose more than placebo.Diabetes, obesity & metabolism, 2018
Fewer patients completed the study with lixisenatide than placebo.Diabetes, obesity & metabolism, 2012

Lixisenatide studies on brain and nerves

21 results · people 0 · animals 19 · lab 2

Top 4 of 21 results

In animals, lixisenatide increased new nerve cell formation in the brain.BMC neuroscience, 2012
In diabetic mice, lixisenatide eye drops protected retinal nerves.Diabetes, 2016
In mice exposed to MPTP, lixisenatide prevented impaired movement.Neuroscience, 2015
In mice with an Alzheimer's disease model, lixisenatide increased hippocampal synaptic plasticity compared with saline.Neuropharmacology, 2014

Lixisenatide studies on immune system and inflammation

13 results · people 0 · animals 11 · lab 2

Top 5 of 13 results

In mice, lixisenatide reduced inflammatory cells in artery plaques compared with vehicle.Diabetologia, 2017
In mice, lixisenatide reduced proinflammatory monocytes.Diabetologia, 2017
In mice with an Alzheimer's disease model, low-dose lixisenatide reduced microglial activation compared with saline.Neuropharmacology, 2014
In mice fed a high-fat diet, no pancreatic inflammation was evident after lixisenatide treatment.Peptides, 2014
In cells, lixisenatide inhibited inflammatory responses through changes in cytokines, tissue-degrading enzymes, and signaling pathways.International immunopharmacology, 2019

Lixisenatide studies on memory and thinking

5 results · people 0 · animals 5 · lab 0

Top 3 of 5 results

In mice with an Alzheimer's disease model, low-dose lixisenatide improved object recognition compared with saline.Neuropharmacology, 2014
In rats, lixisenatide prevented learning and memory impairment compared with amyloid injury without lixisenatide.Neuroscience, 2014
In mice fed a high-fat diet, lixisenatide improved recognition memory.Peptides, 2014

Lixisenatide studies on cells, genes and aging

10 results · people 0 · animals 1 · lab 9

Top 5 of 10 results

In rats with diabetes and brain injury, lixisenatide reduced vascular nitrosative and oxidative stress.Naunyn-Schmiedeberg's archives of pharmacology, 2018
In cells, lixisenatide significantly increased PGC-1α expression.Biochemical and biophysical research communications, 2019
In cells, lixisenatide prevented cell death.International immunopharmacology, 2019
In cells, lixisenatide restored mitochondrial membrane potential.International immunopharmacology, 2019
In cells, lixisenatide improved oxidative stress.International immunopharmacology, 2019

Trials and papers

Lixisenatide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

67 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 67)

25 of 67 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

201520202025

Ph 4
LIRA-LIXI™
NCT01973231
Oct 2013 to Nov 2014
Ph 4
Study on Lixisenatide and Counterregulation to Hypoglycemia
NCT02020629
Dec 2013 to Aug 2015
Ph 4
Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
NCT02049034
Jan 2014 to Jan 2016
Ph 4
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
NCT02200991
Aug 2014 to Nov 2015
Ph 4
ELIXIRS
NCT02276196
Sept 2014 to Apr 2016
Ph 4
EGLIPA
NCT02501850
Oct 2014 to est. Oct 2015
Ph 3
LIXILAN JP-O1
NCT02749890
9 May 2016 to May 2018
Ph 3
LixiLan-G
NCT02787551
6 Jul 2016 to 17 Nov 2018
Ph 4
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
NCT02767596
12 Jul 2016 to 21 Feb 2017
Terminated
Terminated
Ph 4
LixiRam
NCT02941367
23 Feb 2017 to 4 Aug 2017

Browse all 67 matching trials in the list below

25 trials · 3 ongoing · 1 not yet recruiting · 17 completed · 2 stopped early · 5 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT06716424

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Sanofin = 1056 Jan 2025 to 12 Jun 2026

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 10 Jul 2026

RecruitingPhase 4NCT07307235

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Shanghai Zhongshan Hospitaln = 1,31613 Dec 2025 to est. 30 Dec 2027

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 7 Jul 2026

RecruitingPhase 4NCT06671587

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Sanofin = 67810 Dec 2024 to est. 18 Sept 2026

Type 2 Diabetes (T2D)

Trial page ClinicalTrials.govUpdated 17 Mar 2026

Not yet recruitingPhase 4NCT07173712

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Yanbing Lin = 324est. 15 Mar 2026 to est. 31 Dec 2027

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 6 Feb 2026

Enrolling by invitationPhase 4NCT07117240

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

Medical University of Warsawn = 10010 Jul 2025 to est. 10 Jul 2028

Steroid-Induced Diabetes · Steroid-Induced Hyperglycemia · Diabetes

Trial page ClinicalTrials.govUpdated 19 Sept 2025

CompletedPhase 4Results postedNCT05114590

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Sanofin = 12427 Jan 2022 to 14 Apr 2023

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 9 Sept 2025

CompletedPhase 4NCT02049034

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

University of Surreyn = 8Jan 2014 to Jan 2016

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 16 Dec 2024

Status unknownPhase 4NCT05804513

The Effect of Lixisenatide on the Effect of Pituitary Hormones

University of Tartun = 1017 Apr 2023 to est. 31 Dec 2023

Healthy · Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 12 Jun 2023

CompletedPhase 4NCT02941367

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Sanofin = 18423 Feb 2017 to 4 Aug 2017

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Apr 2022

CompletedPhase 4NCT03819790

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

LMC Diabetes & Endocrinology Ltd.n = 1192 Oct 2018 to 19 Nov 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Feb 2021

TerminatedPhase 4NCT02767596

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

Laniado Hospitaln = 212 Jul 2016 to 21 Feb 2017

Diabetes Mellitus Type 2

Trial page ClinicalTrials.govUpdated 7 Apr 2017

CompletedPhase 4Results postedNCT01973231

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 404Oct 2013 to Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 9 Feb 2017

CompletedPhase 4NCT02200991

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Sanofin = 136Aug 2014 to Nov 2015

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 5 Oct 2016

CompletedPhase 4NCT02276196

Effect of LIXIsenatide on the Renal System

Amsterdam UMC, location VUmcn = 40Sept 2014 to Apr 2016

Diabetic Kidney Disease · Diabetic Nephropathy · Diabetes Mellitus · Glucagon-Like Peptide 1

Trial page ClinicalTrials.govUpdated 29 Apr 2016

CompletedPhase 4NCT02020629

Study on Lixisenatide and Counterregulation to Hypoglycemia

Lund Universityn = 18Dec 2013 to Aug 2015

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 15 Dec 2015

Status unknownPhase 4NCT02501850

The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

Hospital Universitari Vall d'Hebron Research Instituten = 40Oct 2014 to est. Oct 2015

Diabetes Mellitus Type 2

Trial page ClinicalTrials.govUpdated 21 Jul 2015

CompletedPhase 3Results postedNCT05413369

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Sanofin = 5827 Jul 2022 to 20 Oct 2023

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 24 Sept 2025

CompletedPhase 3NCT03798054

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Sanofin = 87815 Feb 2019 to 1 Mar 2021

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 19 Jul 2022

CompletedPhase 3NCT03798080

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Sanofin = 42619 Feb 2019 to 1 Dec 2020

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 19 Jul 2022

CompletedPhase 3NCT03529123

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Sanofin = 24719 Jun 2018 to 25 Nov 2019

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 25 Apr 2022

CompletedPhase 3NCT03767543

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Sanofin = 26511 Mar 2019 to 23 Oct 2020

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 25 Apr 2022

TerminatedPhase 3Results postedNCT03434119

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Sanofin = 24120 Feb 2018 to 7 Jan 2019

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 28 Mar 2022

CompletedPhase 3Results postedNCT02787551

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Sanofin = 5146 Jul 2016 to 17 Nov 2018

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 25 Mar 2022

CompletedPhase 3NCT03130426

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Population Health Research Instituten = 16127 Jun 2017 to 30 Sept 2020

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 13 Nov 2020

CompletedPhase 3NCT02749890

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Sanofin = 3219 May 2016 to May 2018

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 16 Jun 2020

9 more mention it but do not test it. They are not trials of Lixisenatide: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

426 studies match. Retracted studies are left out.

Showing 24 of 426 studiesquery qry_04a9702115666aeaef79fa9e

Studies with results

116 studies in all, 19 on this page

Randomized controlled trial · 2015

8 results

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer et al. 2015The New England journal of medicinen = 6,068cited by 1,765

PMID 26630143DOI 10.1056/nejmoa1509225PUB-26630143

Rights unknown8 results where Lixisenatide was given

Source link See results (8)

Animal study (in vivo) · 2012

8 results

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.

Hunter et al. 2012BMC neurosciencecited by 430

PMID 22443187PMC3352246DOI 10.1186/1471-2202-13-33PUB-22443187

CC BY4 results where Lixisenatide was given

Download PDF See results (8)

Randomized controlled trial · 2024

5 results

Trial of Lixisenatide in Early Parkinson's Disease.

Meissner et al. 2024The New England journal of medicinen = 156cited by 298

PMID 38598572DOI 10.1056/nejmoa2312323PUB-38598572

Full text at the publisher5 results where Lixisenatide was given

Publisher page See results (5)

Randomized controlled trial · 2013

10 results

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).

Riddle et al. 2013Diabetes caren = 495cited by 239

PMID 23628617PMC3747925DOI 10.2337/dc12-2454PUB-23628617

Free to read · publisher termsCC BY-NC-ND10 results where Lixisenatide was given

Read at source See results (10)

Animal study (in vivo) · mouse · 2016

7 results

Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.

Hernández et al. 2016Diabetescited by 230

PMID 26384381DOI 10.2337/db15-0443PUB-26384381

Full text at the publisher2 results where Lixisenatide was given

Publisher page See results (7)

Randomized controlled trial · 2012

15 results

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Seino et al. 2012Diabetes, obesity & metabolismcited by 222

PMID 22564709PMC3466411DOI 10.1111/j.1463-1326.2012.01618.xPUB-22564709

CC BY15 results where Lixisenatide was given

Download PDF See results (15)

Randomized controlled trial · 2013

7 results

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Riddle et al. 2013Diabetes caren = 446cited by 217

PMID 23564915PMC3747901DOI 10.2337/dc12-2462PUB-23564915

Free to read · publisher termsCC BY-NC-ND7 results where Lixisenatide was given

Read at source See results (7)

Randomized controlled trial · 2015

20 results

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.

Meier et al. 2015Diabetes caren = 142cited by 214

PMID 25887358DOI 10.2337/dc14-1984PUB-25887358

Full text at the publisher10 results where Lixisenatide was given

Publisher page See results (20)

Animal study (in vivo) · mouse · 2015

10 results

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Liu et al. 2015Neurosciencecited by 209

PMID 26141845DOI 10.1016/j.neuroscience.2015.06.054PUB-26141845

Full text at the publisher5 results where Lixisenatide was given

Publisher page See results (10)

Randomized controlled trial · 2018

9 results

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.

Muskiet et al. 2018The lancet. Diabetes & endocrinologyn = 6,063cited by 203

PMID 30292589DOI 10.1016/s2213-8587(18)30268-7PUB-30292589

Full text at the publisher9 results where Lixisenatide was given

Publisher page See results (9)

Randomized controlled trial · 2013

20 results

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Rosenstock et al. 2013Diabetes caren = 634cited by 200

PMID 23698396PMC3781502DOI 10.2337/dc12-2709PUB-23698396

Free to read · publisher termsCC BY-NC-ND10 results where Lixisenatide was given

Read at source See results (20)

Randomized controlled trial · 2012

14 results

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Fonseca et al. 2012Diabetes caren = 361cited by 167

PMID 22432104PMC3357248DOI 10.2337/dc11-1935PUB-22432104

Free to read · publisher termsCC BY-NC-ND14 results where Lixisenatide was given

Read at source See results (14)

Randomized controlled trial · 2013

25 results

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza et al. 2013Diabetes, obesity & metabolismn = 148cited by 151

PMID 23368510PMC3752965DOI 10.1111/dom.12076PUB-23368510

CC BY12 results where Lixisenatide was given

Download PDF See results (25)

Animal study (in vivo) · mouse · 2014

16 results

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.

McClean et al. 2014Neuropharmacologycited by 150

PMID 25107586DOI 10.1016/j.neuropharm.2014.07.015PUB-25107586

Full text at the publisher11 results where Lixisenatide was given

Publisher page See results (16)

Randomized controlled trial · 2013

14 results

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

Ahrén et al. 2013Diabetes caren = 510cited by 148

PMID 23536584PMC3747937DOI 10.2337/dc12-2006PUB-23536584

Free to read · publisher termsCC BY-NC-ND14 results where Lixisenatide was given

Read at source See results (14)

Randomized controlled trial · 2013

5 results

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.

Lorenz et al. 2013Regulatory peptidesn = 43cited by 123

PMID 23665027DOI 10.1016/j.regpep.2013.04.001PUB-23665027

Full text at the publisher5 results where Lixisenatide was given

Publisher page See results (5)

Randomized controlled trial · 2013

8 results

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

Pinget et al. 2013Diabetes, obesity & metabolismn = 484cited by 119

PMID 23627775DOI 10.1111/dom.12121PUB-23627775

Full text at the publisher8 results where Lixisenatide was given

Publisher page See results (8)

Animal study (in vivo) · mouse · 2017

18 results

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.

Á et al. 2017Diabetologiacited by 118

PMID 28608285DOI 10.1007/s00125-017-4330-3PUB-28608285

Rights unknown15 results where Lixisenatide was given

Source link See results (18)

Randomized controlled trial · 2010

12 results

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.

Ratner et al. 2010Diabetic medicine : a journal of the British Diabetic Associationcited by 115

PMID 20722676PMC3068287DOI 10.1111/j.1464-5491.2010.03020.xPUB-20722676

CC BY12 results where Lixisenatide was given

Download PDF See results (12)

More studies

255 studies in all, 5 on this page

PubMed tag: none · 2017

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.

Hinnen et al. 2017Diabetes spectrum : a publication of the American Diabetes Associationcited by 293

PMID 28848315PMC5556578DOI 10.2337/ds16-0026PUB-28848315

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2016

Corrected

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Rosenstock et al. 2016Diabetes carecited by 220

PMID 27527848DOI 10.2337/dc16-0917PUB-27527848

Full text at the publisher

Publisher page Read the notice

PubMed tag: Randomized Controlled Trial, Multicenter Study · 2016

Corrected

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

Aroda et al. 2016Diabetes carecited by 218

PMID 27650977DOI 10.2337/dc16-1495PUB-27650977

Full text at the publisher

Publisher page Read the notice

PubMed tag: none · 2022

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.

Liu et al. 2022Frontiers in endocrinologycited by 187

PMID 36568085PMC9770009DOI 10.3389/fendo.2022.1043789PUB-36568085

CC BY

Download PDF

PubMed tag: none · 2020

Corrected

Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

Salameh et al. 2020Biochemical pharmacologycited by 164

PMID 32755557PMC7606641DOI 10.1016/j.bcp.2020.114187PUB-32755557

Rights unknown

Source link Read the notice

No result for Lixisenatide (1 study on this page, 55 in all)

These studies name Lixisenatide but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Meta-Analysis · 2017

6 results

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.

Monami et al. 2017Diabetes, obesity & metabolismcited by 189

PMID 28244632DOI 10.1111/dom.12926PUB-28244632

Full text at the publisher6 results

Publisher page See results (6)

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Lixisenatide studies: 116 papers with results

Page 1 of 3

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA · The New England journal of medicine · 2015
Randomized controlled trial · 8 results
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
Rosenstock J · Diabetes care · 2013
Randomized controlled trial · 20 results
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 6 results
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Kaneto H · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 6 results
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Riddle MC · Diabetes care · 2013
Randomized controlled trial · 10 results
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Pinget M · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 8 results
Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W · Diabetes, obesity & metabolism · 2018
Randomized controlled trial · 8 results
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
Riddle MC · Diabetes care · 2013
Randomized controlled trial · 7 results
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Nauck M · Diabetes care · 2016
Randomized controlled trial · 25 results
Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C · Diabetes/metabolism research and reviews · 2014
Randomized controlled trial · 11 results
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Fonseca VA · Diabetes care · 2012
Randomized controlled trial · 14 results
Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
Meneilly GS · Diabetes care · 2017
Randomized controlled trial · 4 results
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J · Diabetes care · 2016
Randomized controlled trial · 5 results
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
Watada H · Diabetes care · 2020
Randomized controlled trial · 7 results
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
Van Gaal L · Journal of clinical & translational endocrinology · 2014
Randomized controlled trial · 8 results
Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.
Hassanein MM · Diabetes research and clinical practice · 2019
Randomized controlled trial · 2 results
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG · The New England journal of medicine · 2024
Randomized controlled trial · 5 results
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Kapitza C · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 25 results
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ · Diabetes care · 2015
Randomized controlled trial · 20 results
Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 6 results
Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
Onishi Y · Journal of diabetes investigation · 2015
Randomized controlled trial · 11 results
Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.
Fountoulakis N · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 4 results
Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
Otowa-Suematsu N · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
Randomized controlled trial · 7 results
Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 13 results
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.
Ballav C · Endocrinology, diabetes & metabolism · 2020
Randomized controlled trial · 10 results
Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
Inoue M · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 2 results
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Seino Y · Diabetes, obesity & metabolism · 2012
Randomized controlled trial · 15 results
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
Ratner RE · Diabetic medicine : a journal of the British Diabetic Association · 2010
Randomized controlled trial · 12 results
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).
Bolli GB · Diabetic medicine : a journal of the British Diabetic Association · 2014
Randomized controlled trial · 14 results
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
Rosenstock J · Journal of diabetes and its complications · 2014
Randomized controlled trial · 11 results
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J · Diabetes care · 2016
Randomized controlled trial · 6 results
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W · Diabetes, obesity & metabolism · 2022
Randomized controlled trial · 10 results
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
Seino Y · Diabetes, obesity & metabolism · 2014
Randomized controlled trial · 10 results
Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
Seino Y · Journal of diabetes and its complications · 2015
Randomized controlled trial · 6 results
Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
Dailey GE · Journal of diabetes · 2019
Randomized controlled trial · 6 results
Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
Tonneijck L · American journal of physiology. Renal physiology · 2019
Randomized controlled trial · 5 results
Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
Tonneijck L · Hypertension (Dallas, Tex. : 1979) · 2018
Randomized controlled trial · 12 results
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Muskiet MHA · The lancet. Diabetes & endocrinology · 2018
Randomized controlled trial · 9 results
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Wysham C · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 4 results
Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
Raccah D · Diabetes/metabolism research and reviews · 2015
Randomized controlled trial · 8 results
EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
Mora PF · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2019
Randomized controlled trial · 7 results
Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
Umpierrez GE · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 2 results
Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
Davidson JA · Clinical diabetes and endocrinology · 2020
Randomized controlled trial · 2 results
iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.
Morea N · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 2 results
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Ahrén B · Diabetes care · 2013
Randomized controlled trial · 14 results
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Guo X · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 9 results
Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.
Sahay R · Diabetes research and clinical practice · 2020
Randomized controlled trial · 2 results
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Quast DR · Diabetes care · 2020
Randomized controlled trial · 10 results
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
Lorenz M · Regulatory peptides · 2013
Randomized controlled trial · 5 results
Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
Marathe CS · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
Randomized controlled trial · 5 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Adlyxin · 27 Jul 2016	27 Oct 2026	accessdata.fda.gov (opens in a new tab)
EU	EMA	lyxumia	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA The substance is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

164 safety results for Lixisenatide.

Regulatory:

Human evidence· 163

In patients with diabetes and recent coronary events, death had a lixisenatide-versus-placebo hazard ratio of 0.94, without a significant difference.
Randomized controlled trialn = 6,068
Hazard ratio
0.94
lixisenatide versus placebo
95% CI lower
0.78
hazard ratio
95% CI upper
1.13
hazard ratio
In ELIXA patients, serum creatinine doubling was numerically more frequent with lixisenatide than placebo, without a statistically significant difference.
Randomized controlled trialn = 6,063
Events
41
lixisenatide
Patients
3031
lixisenatide
Incidence
1%
lixisenatide
7 more measurements in the study.
In patients with type 2 diabetes, symptomatic hypoglycaemia incidence was generally comparable between lixisenatide and placebo.
Randomized controlled trialn = 3,188
In patients with type 2 diabetes receiving basal insulin, low blood glucose index was unchanged with lixisenatide versus placebo.
Randomized controlled trialn = 1,198
In adults with type 2 diabetes on metformin, overall adverse event incidence was similar with lixisenatide and exenatide, as was serious adverse event incidence (2.8% vs 2.2%).
Randomized controlled trialn = 634
Incidence of serious adverse events
2.8%
lixisenatide
Incidence of serious adverse events
2.2%
exenatide
In Japanese patients with type 2 diabetes, documented symptomatic hypoglycemia occurred in 14.2% with iGlarLixi versus 12.3% with glargine.
Randomized controlled trialn = 521
Documented symptomatic hypoglycemia
14.2%
iGlarLixi
Documented symptomatic hypoglycemia
12.3%
iGlar
In Japanese adults with type 2 diabetes, documented symptomatic hypoglycemia occurred in 18.8% with iGlarLixi versus 16.7% with glargine.
Randomized controlled trialn = 512
Documented symptomatic hypoglycemia
18.8%
iGlarLixi
Documented symptomatic hypoglycemia
16.7%
iGlar
In patients with diabetes on basal insulin, symptomatic hypoglycemia occurred in 28% with lixisenatide versus 22% with placebo.
Randomized controlled trialn = 495
Symptomatic hypoglycemia incidence
28%
lixisenatide
Symptomatic hypoglycemia incidence
22%
placebo

The top 24 of 163 results.

Doses studied · 59

The doses that these studies used. They are not recommendations.

20 μg once dailyHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 634
20 μgHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 495
20 µg once dailyHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 484
20 µgHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 446
20 µg once dailyHuman
Species
human
Route
Not reported
Duration
26 weeks
Design
Randomized controlled trial · n = 404
20 µg once dailyHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 391

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
20 μg once daily	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 634
20 μg	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 495
20 µg once daily	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 484
20 µg	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 446
20 µg once daily	Human	human	Not reported	26 weeks	Randomized controlled trial · n = 404
20 µg once daily	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 391

6 of 59 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000145
Peptide version: 2
Peptide hash: b2de63edc62542c7…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304192
27 Oct 2026CreatedData version 256720

For developers

curl -s https://pepbank.io/v1/briefs/lixisenatide

Evidence summary for Lixisenatide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Glycemic controlMetabolic and weight	Human: 345 results from 80 studies: 92 increase, 191 decrease, 22 no significant change, 1 mixed, 39 not reported. Strongest design: Randomized controlled trial	Animal: 7 results from 5 studies: 2 increase, 3 decrease, 1 no significant change, 1 mixed. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells)	No results	353
Adverse eventsWhole body	Human: 117 results from 50 studies: 41 increase, 21 decrease, 18 no significant change, 37 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	117
Gastrointestinal adverse eventsGastrointestinal	Human: 38 results from 27 studies: 20 increase, 4 decrease, 14 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	38
Body weightMetabolic and weight	Human: 33 results from 30 studies: 1 increase, 29 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	33
Kidney functionKidney and urinary	Human: 24 results from 5 studies: 8 increase, 6 decrease, 10 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	25
Receptor activity and mechanismPharmacology	Human: 16 results from 6 studies: 1 increase, 9 decrease, 4 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 17 results from 8 studies: 8 increase, 8 decrease, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 12 results from 6 studies: 3 increase, 6 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	45
Gastrointestinal motilityGastrointestinal	Human: 14 results from 6 studies: 6 increase, 8 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	14
PharmacokineticsPharmacology	Human: 11 results from 4 studies: 7 increase, 1 decrease, 3 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 increase. Strongest design: Animal study (in vivo)	No results	No results	13
Appetite and food intakeMetabolic and weight	Human: 9 results from 2 studies: 3 decrease, 6 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	10
Gastrointestinal functionGastrointestinal	Human: 9 results from 3 studies: 3 increase, 3 decrease, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	9
LipidsMetabolic and weight	Human: 9 results from 2 studies: 1 increase, 3 decrease, 2 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	9
Blood pressureCardiovascular	Human: 8 results from 4 studies: 8 increase. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	9

Outcome group	Human	Animal	Lab	Computer model	Total
Glycemic controlMetabolic and weight	Human: 345 results from 80 studies: 92 increase, 191 decrease, 22 no significant change, 1 mixed, 39 not reported. Strongest design: Randomized controlled trial	Animal: 7 results from 5 studies: 2 increase, 3 decrease, 1 no significant change, 1 mixed. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells)	No results	353
Adverse eventsWhole body	Human: 117 results from 50 studies: 41 increase, 21 decrease, 18 no significant change, 37 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	117
Gastrointestinal adverse eventsGastrointestinal	Human: 38 results from 27 studies: 20 increase, 4 decrease, 14 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	38
Body weightMetabolic and weight	Human: 33 results from 30 studies: 1 increase, 29 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	33
Kidney functionKidney and urinary	Human: 24 results from 5 studies: 8 increase, 6 decrease, 10 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	25
Receptor activity and mechanismPharmacology	Human: 16 results from 6 studies: 1 increase, 9 decrease, 4 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 17 results from 8 studies: 8 increase, 8 decrease, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 12 results from 6 studies: 3 increase, 6 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	45
Gastrointestinal motilityGastrointestinal	Human: 14 results from 6 studies: 6 increase, 8 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	14
PharmacokineticsPharmacology	Human: 11 results from 4 studies: 7 increase, 1 decrease, 3 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 increase. Strongest design: Animal study (in vivo)	No results	No results	13
Appetite and food intakeMetabolic and weight	Human: 9 results from 2 studies: 3 decrease, 6 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	10
Gastrointestinal functionGastrointestinal	Human: 9 results from 3 studies: 3 increase, 3 decrease, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	9
LipidsMetabolic and weight	Human: 9 results from 2 studies: 1 increase, 3 decrease, 2 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	9
Blood pressureCardiovascular	Human: 8 results from 4 studies: 8 increase. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	9